Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

Next Previous
X
Search
Trial Profile

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; KITE 718 (Primary)
  • Indications Multiple myeloma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms HERMOSA-1
  • Sponsors Gilead Sciences; Kite Pharma

    • Most Recent Events

    • 23 Aug 2023 Status changed from active, no longer recruiting to discontinued.
    • 22 Jun 2023 Planned End Date changed from 1 May 2023 to 1 Jul 2023.
    • 11 May 2023 Planned End Date changed from 1 Apr 2023 to 1 May 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top